D3 Bio is a biotechnology company dedicated to developing innovative medicines primarily in the fields of oncology and immunology. The company adopts a unique approach to drug development that begins with identifying significant unmet patient needs and market gaps, particularly where current treatments fail to deliver satisfactory outcomes. This patient-centric strategy informs their research and development (R&D) efforts, guiding the selection of appropriate scientific and technological methods to create a robust portfolio of drug candidates. D3 Bio's pipeline includes multiple pre-clinical oncology programs, all of which are designed to target immune pathways or tumor-driving mutations, with the potential to be first-in-class or best-in-class therapies.

The company emphasizes the importance of precision medicine, aiming to tailor treatments to the specific biomarkers of individual patients. D3 Bio's vision is to transform life-threatening cancers into manageable chronic conditions by developing breakthrough therapies that address the unmet needs of cancer patients globally. Their team comprises experienced professionals from leading pharmaceutical companies, bringing a wealth of knowledge in drug discovery, development, and commercialization. D3 Bio's commitment to bridging clinical insights with scientific research underpins its innovative approach to creating effective cancer treatments.

China

Biotechnology company focusing on development and registration of innovative medicines in oncology and immunology.

Cancer

Digestive System Diseases

Endocrine System Diseases

D3 Bio

Colorectal cancer

Non-small cell lung carcinoma

Pancreatic cancer

D3S-001 (mono/combo)

Small Molecule Pharmaceuticals

D3S-002 (mono/combo)

Breast cancer

Gastric cancer

D3L-001

Antibodies

Biologics

Solid tumor/s

D3L-002 (combo)

D3S-003 (mono/combo)

Bladder cancer

D3L-003

Therapeutic

D3 Bio

Company Details